首页> 外文期刊>Human Pathology >Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum
【24h】

Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum

机译:混合表型大颗粒淋巴细胞白血病:大颗粒淋巴细胞白血病谱中的稀有亚型

获取原文
获取原文并翻译 | 示例
       

摘要

Large granular lymphocytic leukemia (LGLL) is a chronic proliferation of cytotoxic lymphocytes in which more than 70% of patients develop cytopenia(s) requiring therapy. LGLL includes T-cell LGLL and chronic lymphoproliferative disorder of natural killer (NK) cells. The neoplastic cells in LGLL usually exhibit a single immunophenotype in a patient, with CD8-positive/αβ T-cell type being the most common, followed by NK-cell, γδ T-cell, and CD4-positive/αβ T-cell types. We investigated a total of 220 LGLL cases and identified 12 mixed-phenotype LGLLs (5%): 7 cases with coexistent αβ T-cell and NK-cell clones and 5 with coexistent αβ and γδ T-cell clones. With a median follow-up of 48 months, the clinicopathological characteristics of these patients seemed similar to those of typical LGLL patients. Treatment was instituted in 9 patients, and 5 patients (55%) attained complete hematologic response or partial response. The therapeutic response rate of this cohort is comparable to the reported overall response rate of 40% to 60% in typical LGLL patients. Three patients who did not receive any treatment had progressive or persistent cytopenias. Interestingly, inverted proportions of 2 clones at disease recurrence were identified in 4 patients (36%) and stable clonal proportions in 7 patients (64%). Mixed-phenotype LGLL is rare, and this study underscores the importance of recognizing this rare type of LGLL in patients who may benefit from LGLL treatment.
机译:大粒状淋巴细胞白血病(LGLL)是一种细胞毒性淋巴细胞的慢性增殖,其中超过70%的患者发育了需要治疗的细胞缺乏症。 LGLL包括T细胞Lgll和天然杀伤(NK)细胞的慢性淋巴抑制症。 Lgll中的肿瘤细胞通常在患者中表现出单一免疫蛋白型,CD8阳性/αβT细胞类型是最常见的,其次是NK细胞,γδT细胞和CD4阳性/αβT细胞类型。我们研究了总共220 Lgll病例,并确定了12例混合表型Lgll(5%):7例,其中共存αβT细胞和NK细胞克隆,5例,具有共存αβ和γδT细胞克隆。随着48个月的中位随访,这些患者的临床病理特征似乎与典型的LGLL患者类似。治疗在9名患者中,5名患者(55%)达到完全血液学反应或部分反应。该队列的治疗响应率与典型的LGLL患者报告的总体反应率为40%至60%。没有接受任何治疗的三名患者具有渐进性或持续的细胞分析。有趣的是,在4名患者(36%)和7名患者中稳定的克隆比例中,鉴定了2例疾病复发的倒置比例(64%)。混合表型Lgll是罕见的,这项研究强调了在可能受益于LGLL治疗的患者中识别这种稀有型LGLL的重要性。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号